[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637088":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":49,"collaborators":11,"id":51,"slug":11,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":11,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Candid Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cizutamig","EXPERIMENTAL",null,[13],"Drug: Cizutamig will be dosed according to the protocol.",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Cizutamig will be dosed according to the protocol.","CND106",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Martin Zhuang","CONTACT","+86 13918519658","martin@candidrx.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Shanghai Ninth People's hospital Shanghai Jiaotong University school of medicines","RECRUITING","Shanghai","Shanghai Municipality","200011","China",{"type":35,"coordinates":36},"Point",[37,38],121.45806,31.22222,{"lat":38,"lon":37},[41,45],{"name":42,"role":23,"phone":43,"phoneExt":11,"email":44},"Huifang Zhou, Ph.D","+86 13661901886","fangzzfang@sjtu.edu.cn",{"name":46,"role":23,"phone":47,"phoneExt":11,"email":48},"Lina Xing, Ph.D","+86 13918035850","jygcp666@126.com",{"type":50,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100637088",false,"NCT07597200","A Clinical Study of Cizutamig in Thyroid Eye Disease","A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of Cizutamig in Patients With Thyroid Eye Disease","Inclusion Criteria:\n\n* 18-75 years old at the time of signing the Informed Consent Form\n* Diagnosis of Graves' Disease with active, moderate to severe TED in accordance with the Chinese Guidelines for the Diagnosis and Treatment of Thyroid-Associated Ophthalmology (2022) at Screening and Day 1\n\nExclusion Criteria:\n\n* Inadequate clinical laboratory parameters at Screening\n* Active infection present\n* Receipt of, or inability to discontinue, any of the excluded therapies\n* History of progressive multifocal leukoencephalopathy\n* History of primary immunodeficiency\n* Central nervous system disorders that the investigator considers would increase risk to the subject\n* Investigator-determined significant comorbidity(ies)\n* Have a diagnosis or history of malignant disease within 5 years prior to Screening\n* Active tuberculosis or lack of documentation of completed treatment for active pulmonary tuberculosis\n* History of severe allergic or anaphylactic reactions to mAb therapy (or recombinant antibody-related fusion proteins) or any constituents of cizutamig\n* Pregnant or breastfeeding women\n* Patients who do not agree to use highly effective contraception as specified in the protocol","ALL","18 Years","75 Years",{"count":61,"type":62},38,"ESTIMATED","INTERVENTIONAL",[65],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with thyroid eye disease (TED).",[68],"Thyroid Eye Disease, TED","2026-05-13",{"date":71,"type":72},"2026-05-19","ACTUAL",{"date":74,"type":72},"2026-05-08",{"date":76,"type":62},"2028-06-30",{"name":5,"class":6},1]